ATNM Actinium Pharmaceuticals Inc
Price (delayed)
$1.95
Market cap
$60.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
-$23.44M
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application
Highlights
ATNM's gross profit has surged by 80% year-on-year
ATNM's revenue has surged by 80% year-on-year
The equity has declined by 17% year-on-year
The quick ratio has decreased by 15% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of ATNM
Market
Valuations
Earnings
Shares outstanding
31.15M
Market cap
$60.75M
Enterprise value
-$23.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
724.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-289.35
Revenue
$81,000
EBIT
-$42.62M
EBITDA
-$41.82M
Free cash flow
-$34M
Per share
Balance sheet
Liquidity
EPS
-$1.51
Free cash flow per share
-$1.13
Book value per share
$1.47
Revenue per share
$0
TBVPS
$2.99
Total assets
$89.86M
Total liabilities
$46.03M
Debt
$1.85M
Equity
$43.84M
Working capital
$77.34M
Debt to equity
0.04
Current ratio
8.95
Quick ratio
8.84
Net debt/EBITDA
2.01
Margins
Efficiency
Dividend
EBITDA margin
-51,628.4%
Gross margin
100%
Net margin
-52,621%
Operating margin
-57,665.4%
Return on assets
-48.9%
Return on equity
-101.7%
Return on invested capital
N/A
Return on capital employed
-53.2%
Return on sales
-52,621%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATNM stock price
How has the Actinium Pharmaceuticals stock price performed over time
Intraday
0%
1 week
13.37%
1 month
-2.01%
1 year
-72.06%
YTD
-61.61%
QTD
-73.65%
Financial performance
How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$81,000
Gross profit
$81,000
Operating income
-$46.71M
Net income
-$42.62M
Gross margin
100%
Net margin
-52,621%
ATNM's gross profit has surged by 80% year-on-year
ATNM's revenue has surged by 80% year-on-year
The net margin has increased by 49% YoY and by 8% from the previous quarter
Actinium Pharmaceuticals's operating margin has increased by 46% YoY and by 6% from the previous quarter
Growth
What is Actinium Pharmaceuticals's growth rate over time
Valuation
What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.32
P/S
724.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-289.35
The EPS has grown by 17% YoY and by 12% from the previous quarter
The price to book (P/B) is 70% lower than the last 4 quarters average of 4.4 and 63% lower than the 5-year quarterly average of 3.6
The equity has declined by 17% year-on-year
ATNM's revenue has surged by 80% year-on-year
Efficiency
How efficient is Actinium Pharmaceuticals business performance
The ROS has grown by 49% YoY and by 8% from the previous quarter
ATNM's return on equity is down by 36% year-on-year but it is up by 3.1% since the previous quarter
The company's return on assets fell by 14% YoY but it rose by 6% QoQ
Dividends
What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATNM.
Financial health
How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 95% more than its total liabilities
Actinium Pharmaceuticals's current ratio has decreased by 15% QoQ and by 14% YoY
The quick ratio has decreased by 15% from the previous quarter and by 11% YoY
The debt is 96% less than the equity
The debt has decreased by 21% YoY and by 7% from the previous quarter
The company's debt to equity fell by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.